These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

555 related articles for article (PubMed ID: 29057236)

  • 1. Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer.
    Voong KR; Feliciano J; Becker D; Levy B
    Ann Transl Med; 2017 Sep; 5(18):376. PubMed ID: 29057236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
    Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
    JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression testing in non-small cell lung cancer.
    Teixidó C; Vilariño N; Reyes R; Reguart N
    Ther Adv Med Oncol; 2018; 10():1758835918763493. PubMed ID: 29662547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
    Hijazi A; Antoniotti C; Cremolini C; Galon J
    Oncoimmunology; 2023; 12(1):2243169. PubMed ID: 37554310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer.
    Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q
    Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
    Dempke WCM; Fenchel K; Dale SP
    Transl Lung Cancer Res; 2018 Sep; 7(Suppl 3):S275-S279. PubMed ID: 30393621
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The next generation of immunotherapy: keeping lung cancer in check.
    Somasundaram A; Burns TF
    J Hematol Oncol; 2017 Apr; 10(1):87. PubMed ID: 28434399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers.
    Mohanty SK; Mishra SK; Amin MB; Agaimy A; Fuchs F
    Adv Anat Pathol; 2023 May; 30(3):174-194. PubMed ID: 37037418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 testing for lung cancer in the UK: recognizing the challenges for implementation.
    Cree IA; Booton R; Cane P; Gosney J; Ibrahim M; Kerr K; Lal R; Lewanski C; Navani N; Nicholson AG; Nicolson M; Summers Y
    Histopathology; 2016 Aug; 69(2):177-86. PubMed ID: 27196116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
    Tamanna MT; Egbune C
    Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
    Hendriks LE; Rouleau E; Besse B
    Transl Lung Cancer Res; 2018 Dec; 7(6):647-660. PubMed ID: 30505709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies.
    To KKW; Fong W; Cho WCS
    Front Oncol; 2021; 11():635007. PubMed ID: 34113560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers of Immune Checkpoint Blockade Response in Triple-Negative Breast Cancer.
    Isaacs J; Anders C; McArthur H; Force J
    Curr Treat Options Oncol; 2021 Mar; 22(5):38. PubMed ID: 33743085
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology.
    Gridelli C; Ardizzoni A; Barberis M; Cappuzzo F; Casaluce F; Danesi R; Troncone G; De Marinis F
    Transl Lung Cancer Res; 2017 Jun; 6(3):373-386. PubMed ID: 28713682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer.
    Chen R; Tao Y; Xu X; Shan L; Jiang H; Yin Q; Pei L; Cai F; Ma L; Yu Y
    Discov Med; 2018 Oct; 26(143):155-166. PubMed ID: 30586539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
    Krieger T; Pearson I; Bell J; Doherty J; Robbins P
    Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive Capability of PD-L1 Protein Expression for Patients With Advanced NSCLC: Any Differences Based on Histology?
    Meshulami N; Tavolacci S; de Miguel-Perez D; Rolfo C; Mack PC; Hirsch FR
    Clin Lung Cancer; 2023 Jul; 24(5):401-406. PubMed ID: 37208221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.